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Abstract. Amyloid imaging represents a major advance in neuroscience, enabling the detection and quantification of pathologic
protein aggregations in the brain. In this review we survey current amyloid imaging techniques, focusing on positron emission
tomography (PET) with 11carbon-labelled Pittsburgh Compound-B (11C-PIB), the most extensively studied and best validated
tracer. PIB binds specifically to fibrillar beta-amyloid (Aβ) deposits, and is a sensitive marker for Aβ pathology in cognitively
normal older individuals and patients with mild cognitive impairment (MCI) and Alzheimer’s disease (AD). PIB-PET provides
us with a powerful tool to examine in vivo the relationship between amyloid deposition, clinical symptoms, and structural and
functional brain changes in the continuum between normal aging and AD. Amyloid imaging studies support a model in which
amyloid deposition is an early event on the path to dementia, beginning insidiously in cognitively normal individuals, and
accompanied by subtle cognitive decline and functional and structural brain changes suggestive of incipient AD. As patients
progress to dementia, clinical decline and neurodegeneration accelerate and proceed independently of amyloid accumulation. In
the future, amyloid imaging is likely to supplement clinical evaluation in selecting patients for anti-amyloid therapies, while MRI
and FDG-PET may be more appropriate markers of clinical progression.
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1. Introduction
The development of techniques for imaging brain
amyloid protein aggregations in vivo represents a ma-
jor breakthrough in clinical neuroscience. Amyloid
imaging provides our first “real time” glance into the
evolution of brain pathology with aging and disease,
and allows us to ask questions about the relationship
between amyloid pathology and clinical measures in
ways that were never before feasible. The advent
of amyloid imaging comes at an opportune time for
Alzheimer’s disease (AD) research, as the “amyloid
hypothesis” is increasingly challenged due to the fail-
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ure of therapies targeting beta-amyloid (Aβ) to demon-
strate efficacy in clinical trials [1]. Amyloid imag-
ing allows us to critically readdress questions about
the relationship between Aβ aggregation and AD that
have not been definitively answered by post-mortem
studies, including the significance of Aβ aggregation
in cognitively normal individuals, and the relation-
ship between the distribution and burden of amyloid
pathology and clinical features of AD [2–6]. Fur-
thermore, amyloid imaging has the potential to detect
Aβ pathology in very mildly affected or even asymp-
tomatic individuals, when amyloid-modifying thera-
pies may have the highest likelihood of success [7].
In this review we will survey the currently available
amyloid imaging markers, focusing on the most exten-
sively validated tracer, 11C-labelled [N -methyl]-2-(4’-
methylaminophenyl)-6-hydroxybenzothiazole (Pittsb-
urgh Compound-B, PIB). We will then review the rapid-
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ly expanding literature applying PIB-PET to study cog-
nitively normal volunteers and patients with mild cog-
nitive impairment (MCI) and AD, and summarize what
PIB-PET studies have taught us thus far about the rela-
tionship between amyloid, aging and dementia.
2. Amyloid imaging markers
The first published attempt to image amyloid in vivo
was reported by Friedland and colleagues, who admin-
istered a technetium-99 labeled anti-Aβ monoclonal
antibody fragment to AD patients imaged with single
photon emission computed tomography (SPECT) [8].
While this attempt was not successful, as the antibody
proved too large to effectively cross the blood-brain
barrier, it instructed future attempts to develop amyloid
imaging agents, focusing efforts on small molecules
with increased brain permeability.
The first successful amyloid imaging agent em-
ployed in humans was 18fluoro-labelled1,1-dicyano-2-
[6-(dimethylamino)-2-naphthalenyl]propene (FDDNP),
a fluorinated derivative of a nonspecific cell membrane
dye [9]. FDDNP binds in vitro to amyloid conforma-
tions of Aβ, tau and prion protein [9,10], and in 2002
Shoghi-Jadid and coworkers demonstrated increased
tracer binding on positron emission tomography (PET)
in 9 patients with AD compared to 7 matched con-
trols [11]. Tracer retention was highest (30% greater
than the pons reference region) in medial temporal cor-
tex, hippocampus and amygdala, regions which typical-
ly show dense neurofibrillary tangles (NFTs), and was
also increased 10–15% above baseline in frontal, tem-
poral and parietal cortex, regions which typically show
both Aβ plaques and NFTs. In one patient who later
came to autopsy, increased FDDNP-PET signal during
life co-localized to regions with significant plaque and
tangle pathology post-mortem [12].
The most widely studied amyloid imaging agent is
PIB, an analog of the amyloid-binding dye Thioflavin-
T. In vitro, PIB binds specifically to extracellular and
intravascular fibrillar Aβ deposits in post-mortem AD
brains [13–16]. At PET tracer concentrations, PIB
does not appreciably bind to other protein aggregates
such as NFTs or Lewy bodies [13,16,17]. PIB does
bind non-specifically to white matter, likely due to de-
layed clearance of the lipophilic compound from white
matter [18]. In 2004 Klunk and colleagues reported
the first human study of PIB-PET [19]. Thirteen of
16 mild AD patients demonstrated elevated PIB-PET
signal in frontal, parietal and lateral temporal cortex
and the striatum, compared to a reference region in
the cerebellum (which shows low levels of fibrillar Aβ
pathology even in advanced AD [20]). One of nine
cognitively normal controls also showed elevated cor-
tical binding [19]. At a group level, PIB cortical signal
in patients was 1.5–2 times higher in patients compared
to controls [19]. PIB has subsequently been shown to
correlate inversely with cerebrospinal fluid (CSF) lev-
els of Aβ1−42, another in vivo marker of Aβ patholo-
gy [21–23]. Most convincingly, detailed post-mortem
study of two patients who showed elevated PIB-PET
signal during life demonstrated strong correlations be-
tween regional in vivo PET signal and in vitro measures
of Aβ pathology (both plaques and vascular amyloid)
found at autopsy [16,24].
FDDNP and PIB have different binding properties
and distinct advantages and disadvantages. FDDNP
binds to both Aβ and tau amyloid conformations, and
thus accounts for the full spectrum of AD pathology.
The highest region of FDDNP signal in AD is typically
the medial temporal cortex, a region with high NFT
but low plaque burden [12]. As expected, PIB signal
in medial temporal cortex is not elevated in AD pa-
tients compared to controls [19]. FDDNP also binds
to amyloid conformations of prion protein [10], and
thus may have in vivo utility in prion diseases [25].
On the other hand, PIB appears to be highly specific
for Aβ amyloid, which makes it a better tracer for di-
agnostically discriminating between AD and non-Aβ
dementias [26,27]. FDDNP binding can be disrupt-
ed by commonly used non-steroidal anti-inflammatory
drugs [28], while similar drug interactions have not yet
been reported for PIB. From a practical point of view,
FDDNP is labeled with 18fluourine which has a rela-
tively long half-life of 110 minutes, allowing for poten-
tial commercial production and distribution, as is done
for 18F-fluorodeoxyglucose (FDG). PIB is labeled with
carbon-11, which has a half-life of 20 minutes, limit-
ing its use to PET centers with cyclotrons. However,
the short half-life is a potential advantage for research,
since it allows PIB imaging to be easily combined on
the same day with other PET tracers (e.g. FDG).
In a study directly comparing FDDNP and PIB-
PET in the same subjects (14 AD, 11 MCI and 13
controls), Tolboom and coworkers reported a nearly
10-fold higher binding potential in AD for PIB com-
pared to FDDNP [29]. Global cortical PIB discrimi-
nated the three diagnostic groups, whereas global cor-
tical FDDNP only differentiated between AD and con-
trols. Across groups, PIB correlated more strongly
with cognition than FDDNP. Specific (cortical) ver-
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Fig. 1. PIB and FDG in controls and Alzheimer’s disease (AD). Control 1 demonstrates only non-specific PIB binding to white matter (top row,
left), while Control 2 shows diffuse cortical and striatal PIB binding (middle row, left) that is indistinguishable from binding in a patient with
AD (bottom row, left). However, only the AD patient demonstrates reduced glucose metabolism on FDG-PET (bottom row, right), whereas both
controls show intact resting metabolism (top and middle row, right). PIB images are parametric distribution volume ratio (DVR) images using
a cerebellar reference region, while FDG images are normalized to mean activity in pons. All images are in neurologic orientation. MMSE –
Mini-Mental State Exam.
sus non-specific (white matter and brainstem) binding
could be readily discerned by visual inspection of PIB
images (for demonstration see Fig. 1 from our labora-
tory), whereas quantification was needed to distinguish
subjects with elevated FDDNP. Shin and colleagues re-
ported similar results in 10 AD patients and 10 controls
studied with both tracers, though they found a smaller
discrepancy in effect size in favor of PIB [30]. Both
groups found elevated medial temporal binding with
FDDNP but not with PIB, highlighting the comple-
mentary information gained by combining both trac-
ers. A recent in vitro study compared FDDNP and PIB
binding to sub-adjacent sections from AD pathologic
specimens and found comparatively weak binding of
FDDNP compared to PIB [31]. Of the two agents, on-
ly PIB has been quantitatively validated in vivo com-
pared to autopsy [16,24]. Published reports of FDDNP
have thus far originated in three centers and encom-
pass a limited number of subjects [12,29,30], whereas
PIB studies have been performed in an estimated 3,000
participants in over 40 centers around the globe [32].
A number of additional 11C-labeled PET tracers
have been studied in humans as potential amyloid
imaging markers [33,34]. Though preliminary results
have been encouraging, it seems unlikely at this point
that another 11C-labeled tracer will surpass 11C-PIB
as the gold-standard amyloid PET tracer. Howev-
er, the short half-life of 11C is prohibitive in terms
of adopting 11C-PIB into clinical practice and lim-
its its availability for research. Thus, most cur-
rent efforts are focused on developing a fluourine-
18 labeled tracer of comparable quality to 11C-PIB.
Three potential agents currently being studied are 18F-
AH110690 (a 3’-fluoro analog of PIB), the stilbene
derivative 18F-BAY94-9172 (which performed compa-
rably to 11C-PIB in a preliminary study in AD and con-
trols [35]), and 18F-AV-45 [32,35,36]. Efforts also con-
tinue to develop amyloid imaging agents for SPECT
and MRI (reviewed by Nordberg [37]). In October
2008 an advisory committee for the United States Food
and Drug Administration recommended that autopsy-
confirmed studies be required to validate amyloid imag-
ing agents prior to their approval for clinical use
(http://www.aan.com/elibrary/neurologytoday/?event
=home.showArticle&id=ovid.com:/bib/ovftdb/00132
985-200811200-00003).
3. Amyloid imaging in normal controls
For the remainder of this review we will focus on
PIB, which is the best validated amyloid imaging mark-
er, and survey what we have learned from PIB-PET
studies about the natural history and impact of amy-
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Fig. 2. PIB Index in controls and AD. Box and whisker plots represent median (line), 25th and 75th percentile (box) and 1.5 times interquartile
range (IQR, whiskers) of PIB Index in controls recruited from the Berkeley Aging Cohort (CONT, N = 30, mean age 73.7 ± 6.7, MMSE 29.2
± 1.0), and AD patients evaluated at the University of California San Francisco (N = 38, age 68.4 ± 10.6, MMSE 22.8 ± 4.5). Outliers (PIB
Index between 1.5 and 3 IQR) are denoted by a circle and extreme outliers (PIB Index greater than 3 IQR) by an asterisk. PIB Index represents
mean distribution volume ratio (DVR) in frontal, parietal, lateral temporal and cingulate cortex. The control with the second highest PIB Index
is featured in Fig. 1, middle row.
loid deposition, beginning with cognitively normal old-
er individuals and culminating in dementia. Autop-
sy studies in the past decade have demonstrated that
significant Aβ amyloid can be found post-mortem in
25%–45% of cognitively normal older individuals, and
that the extent and distribution of pathology may be
indistinguishable from that found in AD [4,5,38]. The
first PIB-PET study in humans suggested that PIB may
be sensitive to this pathology, with one of nine normal
controls showing elevated tracer binding [19]. Subse-
quent studies have consistently detected elevated tracer
binding in a subset of normal older volunteers, with the
proportion of “PIB-positive” cases ranging from 10%–
30% depending on the age of the cohort and the thresh-
old for defining PIB-positivity [19,39–45]. In contrast,
elevated binding has not been reported in young normal
controls [39]. Binding in carriers of the apolipoprotein
E4 (Apo E4) genotype is higher than in non-carriers,
with suggestion of a gene dose effect [44]. In most
studies, PIB uptake in older controls falls along a con-
tinuum between the very low binding seen in young
controls and the high levels seen in AD (Fig. 2) [39–
45]. The pattern of binding is similar to AD and dif-
fusely involves prefrontal cortex, lateral and medial
parietal regions, lateral temporal cortex and striatum.
Binding patterns can be more focal, and a number of
studies suggest preferential uptake in prefrontal cortex
and posterior cingulate/precuneus [27,39,42,45], simi-
lar to the regions of earliest amyloid deposition noted
in autopsy studies [46]. A number of controls show
focal binding in occipital cortex, a pattern suggestive
of vascular amyloid deposition [27]. Finally, a minor-
ity of older controls show a distribution and burden of
PIB binding that is essentially indistinguishable from
that seen in AD (Figs 1, 2) [39,40,42,43]. The high
rate of PIB-positivity in normal controls underscores
that a positive PIB scan cannot be interpreted without
a careful clinical evaluation, and emphasizes that amy-
loid imaging alone must not serve as a surrogate for a
clinical diagnosis of AD or dementia.
A major unresolved issue in AD research is whether
cognitively normal persons with amyloid deposition are
on a trajectory towards AD, or whether the pathology
is “benign” in these individuals. Cross-sectional post-
mortem studies have yielded equivocal results in this
regard, with some studies finding no association be-
tween post-mortem amyloid pathology and antemortem
cognitive performance, and other studies reporting sub-
tle cognitive deficits in amyloid-positive subjects [4,
38,47,48]. PIB-PET has several potential advantages
over autopsy-based studies in tackling this important
question. First, amyloid imaging allows for more rig-
orous quantification of the distribution and burden of
amyloid, and enables direct comparison of these mea-
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sures to simultaneously-derived cognitive metrics, in
contrast to the significant delay between behavioral as-
sessment and autopsy often seen in post-mortem stud-
ies. Furthermore, PIB-PET has the potential for high-
er throughput than autopsy studies, and, critically, al-
lows investigators to follow amyloid-positive controls
longitudinally to determine their cognitive trajectory.
Cross-sectional studies evaluating the relationship
between PIB binding and cognition in older con-
trol subjects have yielded seemingly conflicting re-
sults. When subjects are dichotomized into “PIB-
positive” and “PIB-negative” groups, most studies have
not found significant differences in cognitive perfor-
mance [27,39,41,42], with the exception of a single
study that found lower episodic memory scores in the
PIB-positive group [40]. However, the sample sizes in
these studies were relatively small (range 20–45 sub-
jects, of whom 4–9 were classified as PIB-positive),
such that they may have been under-powered to find
a subtle effect. In contrast, most studies that evaluat-
ed PIB as a continuous variable have found significant
negative correlations between PIB uptake and episodic
memory scores [40,41,43,45], though these relation-
ships may rely on outliers and appear to vary between
cohorts [43]. These results are not necessarily contra-
dictory, and suggest that continuous regressions may
be more sensitive to the relationship between PIB and
cognition, at least until larger samples are studied and
more objective (i.e. pathology-based) cut-offs for PIB-
positivity are determined.
Two studies have reported negative correlations in
normal controls between PIB uptake and hippocampal
volumes measured by MRI [41,43]. When PIB bind-
ing, hippocampal volume and episodic memory scores
were included in the same model using either multilin-
ear [43] or logistic regression [41], hippocampal atro-
phy appeared to mediate the relationship between PIB
binding and memory loss. Other studies have found re-
ductions in whole-brain volume [49] and cortical thick-
ness in AD-specific regions [50] in PIB-positive nor-
mal controls compared to their PIB-negative counter-
parts. Studies are currently underway to investigate
the relationships between PIB binding in controls and
functional imaging markers of AD, such as glucose hy-
pometabolism and decreased resting state connectivi-
ty [51,52].
While prospective longitudinal data on PIB-positive
controls are not yet available, Villemagne and col-
leagues retrospectively examined cognitive test scores
over 6–10 years in 34 subjects enrolled in the Mel-
bourne Healthy Aging Study [45]. They found that
PIB-positivity was more common in subjects with de-
clining cognitive test scores (70%) than in those with
stable scores (17%). In contrast, the PIB-positive con-
trol in the first PIB-PET study has remained cognitive-
ly stable over five years [53]. Overall, the preponder-
ance of currently available data suggest that at a group
level, PIB uptake in nondemented subjects is associat-
ed with decreased episodic memory performance, and
with structural and functional brain changes suggestive
of incipient AD. Several large longitudinal studies are
currently underway to test this hypothesis more defini-
tively.
4. Amyloid imaging in mild cognitive impairment
Amyloid imaging can potentially identify patients
with MCI who already show Aβ aggregation and are
thus in the early clinical phase of AD, and separate them
from patients with alternative substrates for cognitive
impairment [54]. Such separation may have prognos-
tic implications, assuming that patients with underly-
ing AD are at higher risk of progressing to dementia.
Dividing MCI patients into more biologically homo-
geneous groups may also facilitate their inclusion in
clinical trials for AD-specific therapies, allowing these
treatments to be tested in patients earlier in the disease
course, when therapies may have a higher likelihood of
success [7].
At a group level, MCI patients show PIB uptake that
is intermediate between AD patients and controls [22,
27,40,41,43,55–57]. However, PIB binding levels in
MCI in most studies are bimodal, with a majority of pa-
tients demonstrating AD-like uptake levels, a minority
showing low-control level binding, and a small num-
ber of patients falling in the intermediate range. At
an individual subject level, 52%–87% of MCI patients
show elevated PIB binding, depending on the criteria
used to diagnose MCI and the threshold used to define
PIB-positivity [22,27,40,41,43,55–57]. Patients meet-
ing criteria for amnestic MCI are more likely to be
PIB-positive than patients with non-amnestic MCI [22,
40], and PIB-positivity is also more common in Apo
E4 carriers [40]. Two studies suggest that PIB is more
sensitive than CSF Aβ1−42 levels in detecting amyloid
pathology in MCI [22,57], though this may be an ar-
tifact of choosing more sensitive cut-offs for PIB than
for CSF Aβ.
Cross-sectional comparisons of PIB-positive and
PIB-negative MCI patients reveal lower performance
on episodic memory tasks in PIB-positive patients in
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some studies [40] but not others [27,41]. As in con-
trols, when PIB is examined as a continuous variable,
negative correlations are found between tracer binding
and episodic memory scores [22,40,43], and between
PIB uptake and hippocampal volume [41,43]. In terms
of prognosis, pooled results from three studies with
longitudinal data (range: eight months to two years)
reveal that 17/17 MCI patients that progressed clini-
cally or converted to dementia were PIB-positive [22,
40,57]. While more longitudinal studies are needed,
current data suggest that amyloid imaging may provide
important prognostic information in MCI, and will help
select MCI patients that are candidates for AD-specific
therapies. These sentiments are reflected in the pro-
posed new AD research criteria, in which the diagno-
sis of AD can be made in the absence of dementia in
patients with an amnestic syndrome and PET evidence
of amyloid deposition [58].
5. Amyloid imaging in Alzheimer’s disease
The initial “proof of concept” studies of amyloid
imaging with PIB-PET focused on detecting Aβ amy-
loidosis in patients clinically diagnosed with AD. As
expected, the vast majority of AD patients show elevat-
ed PIB retention as judged either by visual assessment
or by quantification of tracer uptake (Figs 1, 2) [19,26,
27,41,59,60]. Using clinical diagnosis as a gold stan-
dard, the sensitivity of PIB-PET for AD has been re-
ported as 80%–100%, with most studies reporting sen-
sitivities of 90% or greater [19,26,39,60]. The signifi-
cance of a “negative” PIB scan in a patient clinically di-
agnosed with AD is not yet clear due to the lack of post-
mortem data. The proportion of PIB-negative scans in
AD is very similar to the fraction of patients clinically
diagnosed with AD at dementia referral centers who are
subsequently found to have an alternative pathology at
autopsy [61], suggesting that many PIB-negative scans
in AD may represent “true” negatives. One pathology-
confirmed “false-negative” PIB result has been report-
ed thus far, involving a patient with Aβ plaques on
frontal brain biopsy who showed low PIB binding when
studied with PET twenty months later [62]. While the
histopathologic characterization of this case was limit-
ed, it seems likely that PIB will fail to detect amyloid
deposits below a certain threshold, and that, rarely, PIB
may fail to bind to certain human amyloid confirma-
tions, as has been reported in transgenic AD mice [63].
Therefore, while preliminary studies based on clinical
diagnosis are encouraging, the precise sensitivity and
specificity of PIB-PET for AD pathology need to be
determined by post-mortem studies.
The distribution of PIB uptake in patients with AD
closely mirrors the distribution of Aβ fibrillar plaques
found at autopsy [64,65]. Using either voxel-wise or
region-of-interest analysis, highest tracer uptake is con-
sistently found in prefrontal cortex, precuneus and pos-
terior cingulate cortex, followed closely by lateral pari-
etal and temporal cortex and striatum, with relatively
lower tracer uptake in occipital cortex, globus pallidus
and thalamus (Fig. 1) [19,27,41,60,66]. Primary sen-
sorimotor and visual cortex are relatively spared, as are
medial temporal cortex, hippocampus and amygdala.
Cerebellar gray matter shows very little tracer uptake,
mirroring post-mortem findings [20] and making the
cerebellum a convenient reference region for normal-
izing PET counts across subjects [55,67]. One study
reported slightly higher cortical binding in ApoE4 car-
riers versus non-carriers [68]. In most patients the dis-
tribution of tracer uptake is diffuse and symmetric, with
very high inter-correlation between regions [69].
Interestingly, patients with familial AD due to
presenilin-1 (PS1) mutations and familial AD and cere-
bral amyloid angiopathy (CAA) due to reduplication of
the amyloid precursor protein (APP) show an atypical
pattern of PIB retention, with very high tracer uptake in
the striatum and relatively low cortical uptake [70–72].
This distinct binding pattern contrasts with the more
extensive cortical Aβ pathology found at autopsy in
patients from the same pedigrees [70,71]. The explana-
tion for this unusual binding pattern is not clear. Striatal
binding is found in asymptomatic PS-1 mutation car-
riers years before expected symptom onset, suggesting
that striatal amyloid deposition may be an early feature
of familial AD [70]. However, this explanation does
not account for striatal-predominant binding in patients
with moderate dementia in the same pedigrees. An
alternative explanation is that PIB has a lower binding
affinity for Aβ plaques associated with specific AD mu-
tations, perhaps due to microstructural differences in
amyloid, as has been described in AD transgenic mice
(including APP/PS1 mice) [63]. These conformational
differences may interfere to a greater degree with PIB
binding to the compact plaques in neocortex than to
the relatively diffuse plaques in striatum, leading to an
artifact of greater tracer binding in striatum. Again,
autopsy studies are needed to distinguish between these
possibilities.
Most studies have found either weak or absent cor-
relations between PIB uptake and clinical markers of
AD severity such as episodic memory scores, Mini-
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Fig. 3. Relationships between PIB, FDG and AD severity. (A) Voxel-wise parametric regressions between PIB and MMSE (top row) and FDG
and MMSE (bottom row) in 38 AD patients (age 68.4± 10.6, MMSE 22.8± 4.5), controlling for age, sex and education. Images are thresholded
at p < 0.001, uncorrected for multiple comparisons. MMSE correlated positively with FDG in bilateral parietal and left frontal, lateral temporal
and posterior cingulate cortex, while no significant correlations (positive or negative) were found between PIB and MMSE at this threshold. (B)
Regression of PIB Index (mean distribution volume ratio (DVR) in frontal, parietal, lateral temporal and cingulate cortex) versus MMSE (left
panel) and Clinical Dementia Rating Sum of Boxes (CDR-SB, group mean 4.7 ± 2.1, right panel) reveal no significant correlations between
amyloid burden and measures of AD severity.
Mental State Exam (MMSE) [73] and Clinical Demen-
tia Rating [74] (Fig. 3) [19,27,40,60,75–77]. Studies
that found correlations often pooled controls and AD
patients together, or included PIB-negative AD sub-
jects (that tend to have high cognitive scores and low
levels of functional impairment) in the analysis [40,41,
60,75]. Correlations significantly weakened or disap-
peared when controls and PIB-negative AD subjects
were excluded from the analysis [40,60]. The cross-
sectional association between PIB and cognitive mea-
sures is weaker in AD than in MCI and normal con-
trols [40], and grows weaker yet with AD progres-
sion [75]. Across studies, clinical measures are more
tightly linked to brain atrophy (measured by MRI) and
glucose hypometabolism (FDG-PET) than to PIB up-
take (Fig. 3) [41,60,75,77,78]. These findings are con-
sistent with the majority of clinicopathological studies
that have not found a strong correlation between Aβ
amyloid plaque burden and AD severity [2,3,79].
The regional relationship between PIB uptake and
brain structural and functional changes in AD is com-
plex [19,22,41,60,75]. High PIB binding is associated
with hypometabolism and atrophy in lateral and medi-
al (posterior cingulate/precuneus) parietal regions and
lateral temporal cortex, but not in frontal cortex or stria-
tum. Conversely, hypometabolism and atrophy in the
absence of PIB binding are seen in medial temporal cor-
tex and hippocampus. Primary sensorimotor and visual
cortices are spared of amyloid and also remain metabol-
ically and structurally intact. The biological mecha-
nisms that underlie these relationships are not well un-
derstood. The metabolic and structural sparing of stria-
tum despite a high amyloid burden may be explained by
the relatively diffuse (and thus less neurotoxic) nature
of striatal Aβ deposits [80]. However, this rationale
cannot explain the relative sparing of prefrontal cortex,
where neuritic Aβ pathology can be extensive [65,81].
Putative explanations for the markedly selective tem-
poroparietal patterns of atrophy and hypometabolism
seen in AD in the face of diffuse Aβ pathology include:
greater synaptic reserve in prefrontal cortex [82,83],
relative vulnerability of posterior brain regions due to
differences in lifetime metabolic activity or gene ex-
pression patterns [84–86], and differences in the distri-
bution of pathology not captured by PIB, such as sol-
uble Aβ and NFTs [46,87]. Hippocampal and medi-
al temporal injury in the setting of low Aβ deposition
may be largely driven by NFT pathology [88], although
disconnection from medial parietal cortex and high lo-
cal levels of soluble Aβ have also been postulated as
potential mechanisms to explain this discrepancy [85,
87].
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PIB-PET shows low (∼5%) test-retest variability,
and is thus suitable to measure longitudinal changes
in amyloid burden [67,75]. All 16 patients with AD
included in the original PIB-PET study underwent re-
peat imaging 2.0 ± 0.5 years later [75]. At a group
level, there were no significant increases in global or
regional PIB binding, though there was considerable
variability between subjects, with many showing small
increases in PIB and, paradoxically, a number showing
decreases in uptake. There was a clear dissociation
in individual patients between amyloid load, which re-
mained relatively stable, and clinical status, which de-
clined considerably in a number of patients. The clin-
ical decline was much better reflected by decreasing
glucose metabolism measured by FDG-PET. The rate
of cognitive decline correlated with changes in FDG
but not in PIB. Not surprisingly, correlations between
PIB and cognition and PIB and FDG that were observed
in this cohort at baseline were no longer significant at
follow-up. Jack and colleagues found similar results
when examining changes in PIB binding and brain at-
rophy over one year in 21 normal controls, 32 patients
with MCI, and 8 patients with AD [78]. At a group
level there was a small but significant increase in PIB
over one year. The rate of increase was similar across
diagnostic groups and across brain regions. In contrast,
brain atrophy rates (as measured by changes in ventric-
ular volume) were highest in AD, intermediate in MCI
and lowest in controls. Longitudinal clinical decline
correlated strongly with brain atrophy rates but did not
correlate with changes in PIB.
6. Amyloid imaging in other dementia syndromes
PIB can detect Aβ deposition in other dementia
syndromes associated (to varying degrees) with beta-
amyloidosis, including CAA, dementia with Lewy bod-
ies (DLB) and posterior cortical atrophy (PCA) [27,
89–93]. PIB can also be used to exclude atypical pre-
sentations of AD in clinical syndromes typically asso-
ciated with non-Aβ pathology such as frontotemporal
lobar degeneration (FTLD), primary progressive apha-
sia (PPA) and prion disease [25–27,94,95,97]. Patients
with CAA show relatively higher occipital PIB reten-
tion than AD patients [89,98], consistent with the typ-
ical anatomic distribution of this pathology at autop-
sy [99]. Patients with DLB show a deposition pattern
similar to AD, though overall amyloid levels tend to be
lower and inter-subject variability is higher [27,91,92].
Amyloid aggregation in DLB may be associated with
greater cognitive deficits [91,100] and more rapid dis-
ease progression [27]. Single case studies have report-
ed asymmetric left hemisphere PIB uptake in PPA [90]
and posterior-predominant PIB uptake in PCA [90,93].
However, at a group level we have found PIB uptake
in PPA and PCA to be diffuse, symmetric and indistin-
guishable from the pattern seen in AD, whereas atrophy
and glucose hypometabolism patterns are asymmetric
and more closely match the clinical phenotype [94,
101]. Non-amnestic presentations of AD are relatively
common at dementia referral centers [102], and PIB
may have a future role in selecting patients with atypical
clinical symptoms who may be candidates for anti-Aβ
therapies [103].
7. PIB-PET and the amyloid hypothesis:
Integrating the data
Taken together, PIB-PET studies support a model in
which Aβ aggregation is an early event on the path to
dementia. Amyloid accumulation begins insidiously
and progresses slowly in a subset of older individuals.
While the cognitive effects of Aβ deposition in these
healthy older people is debatable, structural and func-
tional imaging studies suggest that the protein has a
deleterious effect that appears similar to AD in several
respects. By the time patients reach the MCI phase
amyloid accumulation already approximates the lev-
els seen in AD, a process which may take over two
decades [78]. As patients progress to mild dementia,
clinical decline and neurodegeneration (as reflected by
MRI and FDG-PET) accelerate and proceed in tight re-
lation to each other, but apparently independent of amy-
loid accumulation, which has either reached a plateau
or continues to progress very slowly.
The data used to derive this model have inherent lim-
itations. First, more rigorous work is needed to es-
tablish the quantitative relationship between PIB bind-
ing and Aβ pathology at various disease stages. It is
conceivable, for example, that PIB binding may reach
a ceiling at high plaque density, and thus fail to cap-
ture the progression of pathology beyond a certain dis-
ease stage. Second, most data are derived from cross-
sectional studies, and need to be verified by longitu-
dinal investigations. Finally, PIB binds only to fibril-
lar Aβ, and apparent dissociations between PIB uptake
and other disease measures may be accounted for by
soluble forms of Aβ that are not reflected by PIB-PET.
With these limitations in mind, this working model of
amyloid aggregation suggests that the optimal time to
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initiate therapies targeting Aβ (at least in its fibrillar
form) may be in the pre-MCI stage, when cognition is
still intact, and neurodegeneration is mild and appears
linked to amyloid levels. By the time patients are in the
mild stages of AD or perhaps even in the MCI stage,
other pathologic processes that are independent of fib-
rillar Aβ may already be in motion, and the therapeutic
window for anti-plaque interventions may already be
closed.
8. Conclusion
In the past five years amyloid imaging has estab-
lished itself alongside MRI and FDG-PET as a core
neuroimaging tool for the evaluation of brain aging and
dementia. In particular, PET imaging with 11C-PIB
appears to be a sensitive and specific diagnostic marker
for underlying Aβ amyloidosis, and can detect pathol-
ogy in patients with early or atypical symptoms as well
as in asymptomatic older adults. PIB-PET has provided
us with our first in vivo glance at the dynamic relation-
ship between amyloid deposition, clinical symptoms,
and structural and functional changes in the brain in
the continuum between normal aging and AD. A num-
ber of promising 18F-labelled imaging markers are cur-
rently under development, and these will allow broad-
er application of amyloid imaging to clinical practice
and research. In the future, Aβ imaging will likely
supplement clinical evaluation in selecting patients for
anti-amyloid therapies both during drug development
and in the clinic, while alternative imaging techniques
such as MRI and FDG-PET may be more appropriate
markers of clinical progression. The development of
in vivo biomarkers for other critical elements of AD
pathogenesis such as soluble Aβ, tau, acetylcholine
and brain inflammation would further inform our un-
derstanding of the complexities of the disease in hu-
mans, and ultimately assist in developing and testing
disease-modifying and perhaps preventive treatments
for AD.
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